Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986416 |
Synonyms | |
Therapy Description |
BMS-986416 (AVID200) is a TGF-beta receptor-based TGF-beta trap, which neutralizes TGF-beta1 and TGF-beta3 without interfering with TGF-beta2, resulting in decreased downstream signaling and potentially leading to increased recruitment and activation of anti-tumor T cells (Cancer Res July 1 2017 (77) (13 Supplement) 4688). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986416 | AVID200|AVID 200|AVID-200|BMS986416|BMS 986416 | BMS-986416 (AVID200) is a TGF-beta receptor-based TGF-beta trap, which neutralizes TGF-beta1 and TGF-beta3 without interfering with TGF-beta2, resulting in decreased downstream signaling and potentially leading to increased recruitment and activation of anti-tumor T cells (Cancer Res July 1 2017 (77) (13 Supplement) 4688). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03895112 | Phase I | BMS-986416 | MPN-RC 118 AVID200 in Myelofibrosis | Completed | USA | 0 |
NCT04943900 | Phase I | BMS-986416 + Nivolumab BMS-986416 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Active, not recruiting | USA | NLD | CAN | BEL | ARG | 2 |
NCT03834662 | Phase I | BMS-986416 | A Trial of AVID200, a Transforming Growth Factor beta (TGFbeta) Inhibitor, in Patients Malignancies | Unknown status | USA | CAN | 0 |